Dr Gregorevic gained his PhD from the University of Melbourne Department of Physiology in 2001. He subsequently trained as a postdoctoral research fellow within the University of Washington Department of Neurology, Seattle USA, where he acquired expertise in molecular biology and the design of recombinant viral vectors as gene delivery technologies for studying and treating muscle diseases. In 2008, Dr Gregorevic relocated his research program to Baker IDI Heart and Diabetes Institute, Melbourne, where he is Head of the Laboratory for Muscle Biology and Therapeutics Development, and Director of the Recombinant Viral Vector Core. His research interests focus on elucidating the mechanisms underlying the development and regulation of the skeletal muscle phenotype, and the development of novel therapeutic interventions to combat loss of muscle function associated with heritable and acquired diseases and the aging process. Dr Gregorevic has authored numerous papers, reviews and book chapters concerning the mechanisms of skeletal muscle function and adaptation, neuromuscular disorders, and intervention strategies for their treatment. He has served as an elected member of the Executive Committee of the Australian Gene Therapy Society since 2009.